Impact of serum MCP-1 and IL-7 concentrations and lymphodepletion intensity on PFS. (A) Kaplan-Meier estimates of PFS according to patients with a favorable cytokine profile (serum day 0 MCP-1 and peak IL-7 concentrations above the median; red) compared with those with an unfavorable cytokine profile (serum day 0 MCP-1 and/or peak IL-7 concentrations below or equal to the median; blue). (B) Kaplan-Meier estimates of PFS in patients who received high-intensity lymphodepletion (LD; red) compared with those who received low-intensity lymphodepletion (blue). (C) Kaplan-Meier estimates of PFS in patients who received high-intensity lymphodepletion and did or did not achieve a favorable cytokine profile (day 0 MCP-1 and peak IL-7 concentrations above the median), and in those who received low-intensity lymphodepletion. (A-C) The numbers of patients at risk at 6-month intervals are indicated. Log-rank tests were used to compare between-group differences in survival probabilities. (D) Association of favorable (red) or unfavorable (blue) cytokine profile and the hazard of a PFS event according to pre-lymphodepletion serum LDH level, with 95% CI depicted in gray. Cytokines were modeled as restricted cubic splines with 3 knots. The horizontal line indicates the HR of a PFS event in the whole cohort. (E) Association of high-intensity (red) or low-intensity (blue) lymphodepletion and the hazard of a PFS event according to pre-lymphodepletion serum LDH level, with 95% CIs depicted in gray. The horizontal line indicates the HR of a PFS event in the whole cohort.